Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | £1 | £1 | £1 | £0 |
| % Growth | -22.8% | 12.8% | 77.6% | – |
| Cost of Goods Sold | £0 | £1 | £1 | £0 |
| Gross Profit | £0 | £0 | £0 | -£0 |
| % Margin | 44.5% | 29.9% | 22.7% | -10% |
| R&D Expenses | £3 | £3 | £3 | £2 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £3 | £5 | £4 | £6 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £7 | £8 | £7 | £8 |
| Operating Income | -£7 | -£8 | -£7 | -£8 |
| % Margin | -976% | -911.6% | -874.3% | -1,876.1% |
| Other Income/Exp. Net | £0 | £0 | £0 | £0 |
| Pre-Tax Income | -£6 | -£8 | -£6 | -£8 |
| Tax Expense | £0 | -£3 | £0 | £0 |
| Net Income | -£6 | -£8 | -£6 | -£8 |
| % Margin | -952.6% | -903.6% | -840.2% | -1,845.8% |
| EPS | -0.021 | -0.019 | -0.032 | -0.041 |
| % Growth | -12.3% | 41.9% | 21.3% | – |
| EPS Diluted | -0.021 | -0.019 | -0.032 | -0.041 |
| Weighted Avg Shares Out | 303 | 241 | 200 | 195 |
| Weighted Avg Shares Out Dil | 303 | 241 | 200 | 195 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£6 | -£4 | -£6 | -£8 |
| % Margin | -926.9% | -487.5% | -837.7% | -1,804.8% |